Prakash Raman
Net worth: 94 582 $ as of 2026-08-30
Net worth: 94 582 $ as of 2026-08-30
Dr. Prakash Raman is an Independent Director at Olema Pharmaceuticals, Inc., a Chief Executive Officer at Indupro, an Independent Director at Black Diamond Therapeutics, Inc., a Chief Executive Officer & Director at InduPro, Inc. and a President, Chief Executive Officer & Director at Ribon Therapeutics, Inc. He is on the Board of Directors at Olema Pharmaceuticals, Inc., Black Diamond Therapeutics, Inc., InduPro, Inc. and Ribon Therapeutics, Inc. Dr. Raman was previously employed as a VP & Global Head-NIBR Business Development by Novartis Institutes for Biomedical Research, Inc. and a Head-Project Management by AstraZeneca PLC.
He also served on the board at KSQ Therapeutics, Inc. and NAYA Therapeutics, Inc. He received his undergraduate degree from Indian Institute of Technology Bombay, a graduate degree from Indian Institute of Technology Bombay and a doctorate degree from the University of Wisconsin-Madison.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-06-25 | 45,039 ( 0.08% ) | 94 582 $ | 2026-08-30 | |
| 2026-06-17 | 0 ( -.--% ) | - $ | 2026-08-30 |
| Companies | Position | Start |
|---|---|---|
| BLACK DIAMOND THERAPEUTICS, INC. | Director/Board Member | 2024-04-09 |
| OLEMA PHARMACEUTICALS, INC. | Director/Board Member | 2026-04-27 |
Ribon Therapeutics, Inc.
Ribon Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops cacner therapies | Chief Executive Officer | 2022-02-16 |
Indupro | Chief Executive Officer | 2024-06-12 |
InduPro, Inc.
InduPro, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that specializes in protein therapeutics and cell-surface platform technologies | Chief Executive Officer | 2024-03-31 |
| Companies | Position | End |
|---|---|---|
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Corporate Officer/Principal | 2019-09-30 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 2012-10-31 |
KSQ Therapeutics, Inc.
KSQ Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops therapeutics for cancer | Chief Executive Officer | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 9 |
|---|---|
AstraZeneca PLC
AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Commercial Services |
Indian Institute of Technology Bombay
Indian Institute of Technology Bombay Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ribon Therapeutics, Inc.
Ribon Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops cacner therapies | Health Technology |
KSQ Therapeutics, Inc.
KSQ Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops therapeutics for cancer | Health Technology |
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops precision medicines for cancer | Health Technology |
Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drugs for the treatment & prevention of estrogen receptor positive breast cancer | Health Technology |
Indupro | |
InduPro, Inc.
InduPro, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that specializes in protein therapeutics and cell-surface platform technologies | Commercial Services |
Select your edition
All financial news and data tailored to specific country editions